ArticleJMA journal2026
Risk Factors for Hot Flashes Associated with Androgen Deprivation Therapy in Japanese Patients with Prostate Cancer.
Article in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Androgen deprivation therapy plays a central role in the treatment of prostate cancer. However, its side effect of hot flashes reduces the quality of life of patients. The risk factors for hot flashes in Japanese patients have been explored in a few studies, but the effects of medications for comorbid conditions have not been fully investigated. This study aimed to determine the risk factors for hot flashes associated with androgen deprivation therapy in Japanese patients with prostate cancer. Methods: We conducted a single-center retrospective cohort study in patients with prostate cancer who received luteinizing hormone-releasing hormone agonists or antagonists at our institution from January 2013 to December 2023. The patient demographics, comorbidities, and association between concomitant medications and hot flash onset were investigated using multivariate logistic regression analysis. Results: Of the 180 eligible patients, 99 (55.0%) experienced hot flashes. Multivariate logistic regression analysis revealed that younger age was associated with an increased risk of hot flashes (odds ratio: 1.056, 95% confidence interval: 1.004-1.110, p = 0.034). Concomitant atrial fibrillation (odds ratio: 0.257, 95% confidence interval: 0.071-0.928, p = 0.038) and beta-blocker use (odds ratio: 0.265, 95% confidence interval: 0.086-0.816, p = 0.021) were associated with a decreased risk of developing hot flashes. Conclusions: Younger age is a risk factor for hot flashes during androgen deprivation therapy in Japanese patients with prostate cancer. Beta-blockers may be promising for preventing or treating hot flashes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.